Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication.

The global market for Long-Acting Injectable (LAI) Antipsychotic was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Long-Acting Injectable (LAI) Antipsychotic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Long-Acting Injectable (LAI) Antipsychotic by region & country, by Type, and by Application.

The Long-Acting Injectable (LAI) Antipsychotic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Injectable (LAI) Antipsychotic.

Market Segmentation

Scope of Long-Acting Injectable (LAI) Antipsychotic - Market Report

Report Metric	Details
Report Name	Long-Acting Injectable (LAI) Antipsychotic - Market
CAGR	5%
Segment by Type:	Aripiprazole Fluphenazine Haloperidol Others
Segment by Application	Hospital Retail Pharmacy Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Alkermes, Eli Lilly and Company, Janssen Global Services, LLC, Abilify Maintena, Haldol, Otsuka Pharmaceutical, Aristada, Prolixin, Sumitomo Dainippon Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Long-Acting Injectable (LAI) Antipsychotic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Long-Acting Injectable (LAI) Antipsychotic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Long-Acting Injectable (LAI) Antipsychotic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Long-Acting Injectable (LAI) Antipsychotic - Market report?

Ans: The main players in the Long-Acting Injectable (LAI) Antipsychotic - Market are Alkermes, Eli Lilly and Company, Janssen Global Services, LLC, Abilify Maintena, Haldol, Otsuka Pharmaceutical, Aristada, Prolixin, Sumitomo Dainippon Pharma

What are the Application segmentation covered in the Long-Acting Injectable (LAI) Antipsychotic - Market report?

Ans: The Applications covered in the Long-Acting Injectable (LAI) Antipsychotic - Market report are Hospital, Retail Pharmacy, Others

What are the Type segmentation covered in the Long-Acting Injectable (LAI) Antipsychotic - Market report?

Ans: The Types covered in the Long-Acting Injectable (LAI) Antipsychotic - Market report are Aripiprazole, Fluphenazine, Haloperidol, Others

1 Market Overview

1.1 Long-Acting Injectable (LAI) Antipsychotic Product Introduction

1.2 Global Long-Acting Injectable (LAI) Antipsychotic Market Size Forecast

1.3 Long-Acting Injectable (LAI) Antipsychotic Market Trends & Drivers

1.3.1 Long-Acting Injectable (LAI) Antipsychotic Industry Trends

1.3.2 Long-Acting Injectable (LAI) Antipsychotic Market Drivers & Opportunity

1.3.3 Long-Acting Injectable (LAI) Antipsychotic Market Challenges

1.3.4 Long-Acting Injectable (LAI) Antipsychotic Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Long-Acting Injectable (LAI) Antipsychotic Players Revenue Ranking (2023)

2.2 Global Long-Acting Injectable (LAI) Antipsychotic Revenue by Company (2019-2024)

2.3 Key Companies Long-Acting Injectable (LAI) Antipsychotic Manufacturing Base Distribution and Headquarters

2.4 Key Companies Long-Acting Injectable (LAI) Antipsychotic Product Offered

2.5 Key Companies Time to Begin Mass Production of Long-Acting Injectable (LAI) Antipsychotic

2.6 Long-Acting Injectable (LAI) Antipsychotic Market Competitive Analysis

2.6.1 Long-Acting Injectable (LAI) Antipsychotic Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Long-Acting Injectable (LAI) Antipsychotic Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Injectable (LAI) Antipsychotic as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Aripiprazole

3.1.2 Fluphenazine

3.1.3 Haloperidol

3.1.4 Others

3.2 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type

3.2.1 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value, by Type (2019-2030)

3.2.3 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Retail Pharmacy

4.1.3 Others

4.2 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application

4.2.1 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value, by Application (2019-2030)

4.2.3 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region

5.1.1 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region (2019-2024)

5.1.3 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region (2025-2030)

5.1.4 Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

5.2.2 North America Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

5.3.2 Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

5.4.2 Asia Pacific Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

5.5.2 South America Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

5.6.2 Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Long-Acting Injectable (LAI) Antipsychotic Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Long-Acting Injectable (LAI) Antipsychotic Sales Value

6.3 United States

6.3.1 United States Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

6.3.2 United States Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

6.4.2 Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

6.5.2 China Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

6.5.3 China Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

6.6.2 Japan Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

6.7.2 South Korea Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

6.8.2 Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019-2030

6.9.2 India Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

6.9.3 India Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Alkermes

7.1.1 Alkermes Profile

7.1.2 Alkermes Main Business

7.1.3 Alkermes Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

7.1.4 Alkermes Long-Acting Injectable (LAI) Antipsychotic Revenue (US$ Million) & (2019-2024)

7.1.5 Alkermes Recent Developments

7.2 Eli Lilly and Company

7.2.1 Eli Lilly and Company Profile

7.2.2 Eli Lilly and Company Main Business

7.2.3 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

7.2.4 Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Revenue (US$ Million) & (2019-2024)

7.2.5 Eli Lilly and Company Recent Developments

7.3 Janssen Global Services, LLC

7.3.1 Janssen Global Services, LLC Profile

7.3.2 Janssen Global Services, LLC Main Business

7.3.3 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

7.3.4 Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Revenue (US$ Million) & (2019-2024)

7.3.5 Abilify Maintena Recent Developments

7.4 Abilify Maintena

7.4.1 Abilify Maintena Profile

7.4.2 Abilify Maintena Main Business

7.4.3 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

7.4.4 Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Revenue (US$ Million) & (2019-2024)

7.4.5 Abilify Maintena Recent Developments

7.5 Haldol

7.5.1 Haldol Profile

7.5.2 Haldol Main Business

7.5.3 Haldol Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

7.5.4 Haldol Long-Acting Injectable (LAI) Antipsychotic Revenue (US$ Million) & (2019-2024)

7.5.5 Haldol Recent Developments

7.6 Otsuka Pharmaceutical

7.6.1 Otsuka Pharmaceutical Profile

7.6.2 Otsuka Pharmaceutical Main Business

7.6.3 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

7.6.4 Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Revenue (US$ Million) & (2019-2024)

7.6.5 Otsuka Pharmaceutical Recent Developments

7.7 Aristada

7.7.1 Aristada Profile

7.7.2 Aristada Main Business

7.7.3 Aristada Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

7.7.4 Aristada Long-Acting Injectable (LAI) Antipsychotic Revenue (US$ Million) & (2019-2024)

7.7.5 Aristada Recent Developments

7.8 Prolixin

7.8.1 Prolixin Profile

7.8.2 Prolixin Main Business

7.8.3 Prolixin Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

7.8.4 Prolixin Long-Acting Injectable (LAI) Antipsychotic Revenue (US$ Million) & (2019-2024)

7.8.5 Prolixin Recent Developments

7.9 Sumitomo Dainippon Pharma

7.9.1 Sumitomo Dainippon Pharma Profile

7.9.2 Sumitomo Dainippon Pharma Main Business

7.9.3 Sumitomo Dainippon Pharma Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

7.9.4 Sumitomo Dainippon Pharma Long-Acting Injectable (LAI) Antipsychotic Revenue (US$ Million) & (2019-2024)

7.9.5 Sumitomo Dainippon Pharma Recent Developments

8 Industry Chain Analysis

8.1 Long-Acting Injectable (LAI) Antipsychotic Industrial Chain

8.2 Long-Acting Injectable (LAI) Antipsychotic Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Long-Acting Injectable (LAI) Antipsychotic Sales Model

8.5.2 Sales Channel

8.5.3 Long-Acting Injectable (LAI) Antipsychotic Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Alkermes plc

Eli Lilly and Company

Janssen Global Services, LLC

Otsuka Pharmaceutical

Sumitomo Dainippon Pharma

List of Tables

Table 1. Long-Acting Injectable (LAI) Antipsychotic Market Trends

Table 2. Long-Acting Injectable (LAI) Antipsychotic Market Drivers & Opportunity

Table 3. Long-Acting Injectable (LAI) Antipsychotic Market Challenges

Table 4. Long-Acting Injectable (LAI) Antipsychotic Market Restraints

Table 5. Global Long-Acting Injectable (LAI) Antipsychotic Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Long-Acting Injectable (LAI) Antipsychotic Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Long-Acting Injectable (LAI) Antipsychotic Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Long-Acting Injectable (LAI) Antipsychotic Product Type

Table 9. Key Companies Time to Begin Mass Production of Long-Acting Injectable (LAI) Antipsychotic

Table 10. Global Long-Acting Injectable (LAI) Antipsychotic Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Injectable (LAI) Antipsychotic as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Long-Acting Injectable (LAI) Antipsychotic Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Long-Acting Injectable (LAI) Antipsychotic Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Long-Acting Injectable (LAI) Antipsychotic Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Long-Acting Injectable (LAI) Antipsychotic Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region (2019-2024) & (%)

Table 27. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Long-Acting Injectable (LAI) Antipsychotic Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Long-Acting Injectable (LAI) Antipsychotic Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Long-Acting Injectable (LAI) Antipsychotic Sales Value, (2025-2030) & (US$ Million)

Table 31. Alkermes Basic Information List

Table 32. Alkermes Description and Business Overview

Table 33. Alkermes Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

Table 34. Revenue (US$ Million) in Long-Acting Injectable (LAI) Antipsychotic Business of Alkermes (2019-2024)

Table 35. Alkermes Recent Developments

Table 36. Eli Lilly and Company Basic Information List

Table 37. Eli Lilly and Company Description and Business Overview

Table 38. Eli Lilly and Company Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

Table 39. Revenue (US$ Million) in Long-Acting Injectable (LAI) Antipsychotic Business of Eli Lilly and Company (2019-2024)

Table 40. Eli Lilly and Company Recent Developments

Table 41. Janssen Global Services, LLC Basic Information List

Table 42. Janssen Global Services, LLC Description and Business Overview

Table 43. Janssen Global Services, LLC Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

Table 44. Revenue (US$ Million) in Long-Acting Injectable (LAI) Antipsychotic Business of Janssen Global Services, LLC (2019-2024)

Table 45. Janssen Global Services, LLC Recent Developments

Table 46. Abilify Maintena Basic Information List

Table 47. Abilify Maintena Description and Business Overview

Table 48. Abilify Maintena Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

Table 49. Revenue (US$ Million) in Long-Acting Injectable (LAI) Antipsychotic Business of Abilify Maintena (2019-2024)

Table 50. Abilify Maintena Recent Developments

Table 51. Haldol Basic Information List

Table 52. Haldol Description and Business Overview

Table 53. Haldol Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

Table 54. Revenue (US$ Million) in Long-Acting Injectable (LAI) Antipsychotic Business of Haldol (2019-2024)

Table 55. Haldol Recent Developments

Table 56. Otsuka Pharmaceutical Basic Information List

Table 57. Otsuka Pharmaceutical Description and Business Overview

Table 58. Otsuka Pharmaceutical Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

Table 59. Revenue (US$ Million) in Long-Acting Injectable (LAI) Antipsychotic Business of Otsuka Pharmaceutical (2019-2024)

Table 60. Otsuka Pharmaceutical Recent Developments

Table 61. Aristada Basic Information List

Table 62. Aristada Description and Business Overview

Table 63. Aristada Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

Table 64. Revenue (US$ Million) in Long-Acting Injectable (LAI) Antipsychotic Business of Aristada (2019-2024)

Table 65. Aristada Recent Developments

Table 66. Prolixin Basic Information List

Table 67. Prolixin Description and Business Overview

Table 68. Prolixin Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

Table 69. Revenue (US$ Million) in Long-Acting Injectable (LAI) Antipsychotic Business of Prolixin (2019-2024)

Table 70. Prolixin Recent Developments

Table 71. Sumitomo Dainippon Pharma Basic Information List

Table 72. Sumitomo Dainippon Pharma Description and Business Overview

Table 73. Sumitomo Dainippon Pharma Long-Acting Injectable (LAI) Antipsychotic Products, Services and Solutions

Table 74. Revenue (US$ Million) in Long-Acting Injectable (LAI) Antipsychotic Business of Sumitomo Dainippon Pharma (2019-2024)

Table 75. Sumitomo Dainippon Pharma Recent Developments

Table 76. Key Raw Materials Lists

Table 77. Raw Materials Key Suppliers Lists

Table 78. Long-Acting Injectable (LAI) Antipsychotic Downstream Customers

Table 79. Long-Acting Injectable (LAI) Antipsychotic Distributors List

Table 80. Research Programs/Design for This Report

Table 81. Key Data Information from Secondary Sources

Table 82. Key Data Information from Primary Sources

Table 83. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Long-Acting Injectable (LAI) Antipsychotic Product Picture

Figure 2. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value (2019-2030) & (US$ Million)

Figure 4. Long-Acting Injectable (LAI) Antipsychotic Report Years Considered

Figure 5. Global Long-Acting Injectable (LAI) Antipsychotic Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Long-Acting Injectable (LAI) Antipsychotic Revenue in 2023

Figure 7. Long-Acting Injectable (LAI) Antipsychotic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Aripiprazole Picture

Figure 9. Fluphenazine Picture

Figure 10. Haloperidol Picture

Figure 11. Others Picture

Figure 12. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Hospital

Figure 15. Product Picture of Retail Pharmacy

Figure 16. Product Picture of Others

Figure 17. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Long-Acting Injectable (LAI) Antipsychotic Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Long-Acting Injectable (LAI) Antipsychotic Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Long-Acting Injectable (LAI) Antipsychotic Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Long-Acting Injectable (LAI) Antipsychotic Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Long-Acting Injectable (LAI) Antipsychotic Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Long-Acting Injectable (LAI) Antipsychotic Sales Value (%), (2019-2030)

Figure 30. United States Long-Acting Injectable (LAI) Antipsychotic Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (%), 2023 VS 2030

Figure 36. China Long-Acting Injectable (LAI) Antipsychotic Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

Figure 38. China Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Long-Acting Injectable (LAI) Antipsychotic Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Long-Acting Injectable (LAI) Antipsychotic Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (%), 2023 VS 2030

Figure 48. India Long-Acting Injectable (LAI) Antipsychotic Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Long-Acting Injectable (LAI) Antipsychotic Sales Value by Type (%), 2023 VS 2030

Figure 50. India Long-Acting Injectable (LAI) Antipsychotic Sales Value by Application (%), 2023 VS 2030

Figure 51. Long-Acting Injectable (LAI) Antipsychotic Industrial Chain

Figure 52. Long-Acting Injectable (LAI) Antipsychotic Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions